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Healthcare is a major component of the contemporary welfare state, and thus 
ensuring public health through product safety is a substantive public concern .
It is universally accepted that all medicines might produce adverse drug reac-
tions (ADRs) during the course of their normal therapeutic use (Belton and the 
European Pharmacovigilance Research Group 1997) . In order to ensure post-mar-
keting authorisation safety, all suspected ADRs must be reported in an accurate 
and timely manner .
Due to the use of living cells, biological medicinal products (so-called biologi-
cals) pose a specific challenge for pharmacovigilance and the accurate reporting of 
ADRs for mainly four reasons: restrictions in clinical trials, sensitivity to changes 
in the manufacturing process, reporting of batch numbers and the establishment 
of valid causality assessments .
For these reasons, the timely and accurate reporting of ADRs is particularly 
important when it comes to the use of biological products . In order to ensure the 
correct and timely attribution of adverse events to the correct biological product 
and batch, the availability of information such as the international non-proprietary 
name, the brand name, the company’s name and the batch number are extremely 
important .
The former European Union (EU) pharmaceuticals legislation (Directive 2001/83/
EC) underwent an extensive reform process since 2006, which resulted in a new 
Directive (2010/84/EU) and Regulation (No 1235/2010) in 2010, bringing about sig-
nificant changes to pharmacovigilance in general and ADR reporting in particular .
The new legislation, in force since July 2012, strengthens the monitoring of 
medicinal products in general and biologicals in particular to ensure public health 
through product safety . The new legislation is geared towards the detection of 
adverse reactions to medicinal products that have been authorised for marketing, 
© The Editor(s) (if applicable) and The Author(s) 2017
M. Kaeding et al., Pharmacovigilance in the European Union,
DOI 10.1007/978-3-658-17276-3_1
2 1   Introduction
and it consists of activities and methods for detecting, assessing, informing on 
and preventing ADRs .
In August 2016 the European Commission (Commission) published its assess-
ment of the new EU pharmacovigilance legislation . The assessment consists of two 
documents, namely the Commission Report titled “Pharmacovigilance-related 
Activities of Member States and the EMA Concerning Medical Products for Hu-
man Use (2012-2014)” and the related Commission staff working document . The 
first document, an eight-page report, mainly explains the role of the relevant actors 
involved (Member States, EMA and the Commission) and the main activities related 
to pharmacovigilance . Further, the report provides statistics on the numbers of 
pharmacovigilance-related reports and activities between 2012 and 2014 (such as 
ADR reports), showing that the situation in Europe has been steadily improving 
since the adoption of the new pharmacovigilance legislation . The Commission staff 
working document is more elaborate (54 pages) and includes additional information 
on activities related to ADR reporting, such as improvements in strengthening patient 
involvement or awareness-raising campaigns (European Commission 2016, 10-12) .
Both Commission documents, however, only scratch the surface and do not go 
into further detail about the overall day-to-day functioning of the pharmacovigilance 
systems in single Member States, the remaining challenges, or factors that might 
impede or incentivise ADR reporting . Most important, they lack country-specific 
and detailed information about the ADR reporting of biologicals .
This also holds for the work conducted by the three-year Joint Action, called 
the “Strengthening Collaboration for Operating Pharmacovigilance in Europe” 
(SCOPE, 2013-2016) . Funded by the Consumers, Health and Food Executive Agen-
cy,1 this collaborative joint action was created to support effective implementation 
of the pharmacovigilance reform . SCOPE aims at delivering practical tools to and 
guidance for nation regulatory authorities to ensure the consistent development 
of pharmacovigilance systems across Europe, including training in key aspects 
of pharmacovigilance and tools and templates that aim to support best practices 
across Europe . SCOPE was divided into eight separate work packages, one of which 
focused on improvements in ADR reporting .
Overall, SCOPE offers a useful source of information for horizontal aspects of 
national pharmacovigilance systems in Europe . It provides a fuller general un-
derstanding of, and develops best practices in, reporting mechanisms for ADRs .
However, SCOPE pays little attention to biologicals . Moreover, its survey data 
does not allow tracing back country-specific information . Therefore, SCOPE does 
1 Executive agencies in the EU are created by the Commission to support the implemen-
tation of specific programmes, inter alia, in the area of public health .
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not contribute to a Member State-specific understanding of reporting mechanisms 
for ADRs regarding biologicals .
In summary, our study focuses on the ADR reporting of biologicals and on 
specific EU Member States representing various types of healthcare systems across 
Europe . Assessing the timely transposition and accurate implementation of the 
European pharmacovigilance framework as described in Directive 2010/84/EU, this 
report aims at identifying major drivers impeding and incentivising appropriate 
ADR reporting in Europe . Our assessment offers a rich and detailed account of 
ADR reporting systems across individual Member States, identifying perceived 
challenges and best practices in order to formulate recommendations on the nec-
essary conditions for robust and effective systems ensuring accurate identification 
and rapid traceability of biological medicines .
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Assessing medical services has become a political issue throughout the industrialised 
world . The utilisation of health services is influenced by the activities of physicians, 
hospitals, professional associations, interest groups, legislative chambers and ad-
ministrators . Furthermore, it is influenced by the competition of rival ideologies . 
Thus, systems can be centralised or decentralised, or possibly fragmented in a 
recentralised state .
Therefore, our research strategy for the EU pharmacovigilance implementation 
project goes beyond single-country studies . Its geographic scope covers six areas, 
distinguishing between ideal systems – namely, state healthcare systems and societal 
healthcare systems (as well as various permutations of mixed systems thereof):
•	 United Kingdom (ideal-type state healthcare system)
•	 Finland (state-based mixed type)
•	 Poland (state-based mixed type)
•	 France (state-based mixed type)
•	 Portugal (societal-based mixed type)
•	 Germany (societal-based mixed type)
Essentially, there are three responsibilities in healthcare: ﬁrst, the ﬁnancing of 
health services through taxation, social insurance contributions or private means; 
second, the provision of healthcare which can be carried out in state-run facilities 
by state-based actors, in societal-based facilities, or in private for-proﬁt facilities 
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by private actors; and third, the regulation by these actors of the various aspects of 
ﬁnancing and provision (Moran 1999; Burau and Blank 2004) . Taken together, the 
ﬁnancing, service provision and regulation of healthcare are three key dimensions 
along which different groups of actors may take on numerous roles and exhibit 
varying levels of engagement . However, in “real” medical care systems, the “state”, 
“societal” and “private” elements tend to coexist alongside each other in all three 
dimensions . Therefore, when analysing changes over time, the mix within categories 
is taken into consideration .
Based on uniform features across all dimensions of healthcare, we identified 
three instances of ideal types . These types comprise state healthcare systems, in 
which ﬁnancing, service provision and regulation are carried out by state actors 
and institutions; societal healthcare systems, in which societal actors take on the 
responsibility of healthcare ﬁnancing, provision and regulation; and ﬁnally pri-
vate healthcare systems, in which all three dimensions fall under the auspices of 
market actors .
In total, six empirical cases illustrate different arrangements for governing the 
medical care sector and their associated political problems . The United Kingdom, 
Finland, Poland, France, Portugal and Germany have different public traditions 
concerning the ratio of individual versus collective responsibility for social welfare 
in general and medical care in particular .
Given their respective histories and patterns of development, Finland and the 
United Kingdom have well-developed prototypes of organisational and political 
arrangements . The United Kingdom is highly centralised and its National Health 
Service (NHS) is directly financed by the central government out of general tax 
revenues . Significant changes have taken place intra-dimensionally such that there 
has been an internal shift of levels . The introduction of an internal market in the 
United Kingdom has not led to a replacement of the state as the main regulator; 
however, the United Kingdom has created some space for self-regulation through 
NHS trusts . Finland, although a unitary state, has granted important financial and 
organisational roles to local authorities, and it has decentralised many health-related 
functions to regional levels .
Germany can be characterised by predominantly social-insurance-based regula-
tion and ﬁnancing combined with a high and increasing share of private healthcare 
provision . In addition, the current growth of state intervention in Germany even 
enlarges the distance to the societal-based ideal type .
Poland is exemplary for Central and Eastern Europe which has changed from 
socialist healthcare systems to social health insurance systems (Dubois and McKee 
2004) and is currently characterised by comparatively weak social insurance sys-
tems actors and a high proportion of healthcare being provided in public hospitals . 
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Despite the low level of tax funding, Poland can still be classiﬁed as the state-based 
mixed type, and only a strengthening of corporate social insurance actors would 
lead to a real system change .
Southern European countries changed from a social insurance type to a nation-
al-health-service type in the late 1970s and early 1980s (Guillén and Matsaganis 
2000) . In contrast to France, however, Portugal maintained elements of the former 
social health insurance scheme and is characterised by weak public authorities 
(Cabiedes and Guillén 2001) .2 Despite the weakness of state authorities, the changes 
of the 1970s and 1980s seem to represent a system shift from a societal-based mixed 
type towards a state-based mixed type (Wendt et al . 2009) .
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The primary assessment program involves a range of research methodologies that 
are both quantitative and qualitative . Based on a mainly threefold methodological 
approach, including qualitative, quantitative and benchmarking methods, the find-
ings and recommendations have emerged from a most appropriate, sequential desk 
and field research process, benchmarking, and interviews across the six selected 
Member States, national (hospital) pharmacist associations, national regulatory 
agencies, and those administering systems for post-marketing safety surveillance 
of biologicals, including spontaneous reporting systems and external stakeholders .
The research strategy for the EU pharmacovigilance implementation project 
comprises five key stages, as outlined below and detailed in the following paragraphs:
•	 Desk-based analysis
•	 Document research
•	 Key informant interviews
•	 In-depth field research
•	 Benchmarking
Desk-based analysis . There is a vast literature on pharmacovigilance dealing with 
incentives of healthcare professionals to report ADRs . This literature was crucial 
for developing analytical categories for both desk-based and field-based research . 
However, given that this literature is part of the health sciences, it is concerned 
2 Spain, in contrast, has experienced reforms of the medical care sector which means that 
it no longer has a societal-type system .
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primarily with individual factors of ADR reporting, and it necessarily neglects 
political implications at the systems level . Furthermore, research designs are mostly 
based on surveys conducted in single case studies, and thus deal with countries 
in isolation . Extending on this literature, the six empirical case studies, based on 
varying organisational and political arrangements, allow for a better contextual-
isation of ADR reporting .
A comparative case study, with cases selected on an ideal-type health system, 
provides for added benefit to the existing literature .
Document research . Assessing the transposition of the European pharmacovigilance 
framework involved conducting a documentation review . This first phase helped 
collect useful information on the timely and correct transposition, management 
and governance of compliance with Directive 2010/84/EU across all EU-28 Mem-
ber States . Information on the EU pharmacovigilance Directive was taken from 
the official legal database of the EU, which covers all Member State legislation and 
provides publication references regarding Member States’ national provisions to 
enact EU legislation . Because Member States often transpose EU legislation by 
using more than one national transposing instrument, we recorded all transposing 
instruments that were indicated to the Commission until March 2016 . Because the 
recorded measures do not indicate whether the national implementation process 
is complete, a second step was put in place .
Key informant interviews . It is essential that practitioners, industry and regulators 
participate in the reporting of suspected ADRs in order to ensure accurate trace-
ability back to the manufacturer . Consequently, formal schemes were established 
in every country to enable healthcare professionals and the public to report ADRs .
This step involved a series of in-depth interviews which were carried out, either 
face-to-face or by telephone, with different stakeholder groups to map the national 
pharmacovigilance systems . We developed a list of potential interview partners who 
would be relevant for the study, and from this list of stakeholders, we conducted 33 
key informant interviews with executives, healthcare professionals, the industry 
and patient organisations between April and September 2016 .
On the basis of these interviews, the country chapters mapping the respective 
national pharmacovigilance systems were finalised and a first set of perceived best 
practices and challenges was drafted .
In-depth field research . The third step in assessing the European pharmacovigilance 
framework as described in Directive 2010/84/EU involved in-depth study and visits 
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to the six selected countries . This step also helped us compare the different national 
systems and develop recommendations .
Simultaneously, monitoring data provided in documents, websites and reports 
reflecting the current state of play of academic literature was performed . This has 
included collecting details on the number and features of adverse drug reporting, 
incurred by the following studies:
•	 Andrews, E ., Moore, N . (eds) (2014) . Mann’s Pharmacovigilance . Wiley-Black-
well Oxford .
•	 Drozd et al . (2014) . Biosimilar Drugs – Automatic Substitution Regulations Re-
view. Polish ISPOR Chapter’s Therapeutic Programmes and Pharmaceutical Care 
(TPPC) Task Force Report . Journal of Health Policy 1: 52-57 .
•	 European Commission (2016) . Pharmacovigilance Related Activities of Member 
States and the European Medicines Agency Concerning Medicinal Products for 
Human Use (2012-2014), COM(2016) 498 final, Brussels, 08 .08 .2016 .
•	 SCOPE (2016) . Work Package 4 – ADR Collection .
•	 Vermeer et al . (2015) . Traceability of Biologicals: Present Challenges in Pharma-
covigilance . Expert Opinion on Drug Safety 14 (1) .
Benchmarking . Benchmarking analysis included a comparative assessment of cases 
highlighting perceived best practices versus perceived challenges in developing 
national systems, allowing for the identification of biologicals by brand name and 
batch number .
By utilising these comparative materials, we were able to see the relative strengths 
as well as the chronic problems of the EU pharmacovigilance system . Drawing on 
desk- and field-based research, these findings complement and add significantly 
to primarily theoretical discussions about the system (see Borg et al . 2015; Calvo 
and Zuňiga 2014) . The research distinguishes the malleable from the inevitable in 
health-related decision-making across Europe and thereby suggests the constrained 
nature of policy options in Western democratic societies .
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1.4  Summary of Evidence
1.4  Summary of Evidence
This study presents our findings and conclusions that were formed by assessing all 
of the elements in the cumulative process described here . Additional interviews 
were conducted to validate the emerging conclusions that we reached from the 
benchmarking analysis and field and desk research . We weighed all evidence 
equally, except when the evidence was clearly unrepresentative or not credible . In 
cases where we do not provide specific evidence to support a finding or conclusion, 
it is because we have combined the evidence to present a summary conclusion . The 
recommendations are based on our own analysis .
1.5  Implementation Assessment Structure
1.5  Implementation Assessment Structure
The main purpose of this EU pharmacovigilance implementation study is to present 
the findings of the comparative assessment of six national ADR reporting systems 
for biologicals and to outline recommendations for future action . After having 
put the implementation assessment into context and taking into account the com-
plexity of the study through a threefold methodological approach, we determined 
six important goals, corresponding to the following structure of the manuscript:
•	 Chapter 2: Pharmacovigilance . This chapter outlines the fundamentals of phar-
macovigilance with a particular emphasis on the role of healthcare professionals 
when it comes to ADR reporting . The chapter also explains why pharmacovig-
ilance is specifically important regarding biologicals .
•	 Chapter 3: The EU Pharmacovigilance System . This chapter outlines the main 
objectives of pharmaceutical regulation in the EU, tracing the developments in 
terms of pharmacovigilance . It identifies the complex network of EU actors and 
presents the key features of the current EU pharmacovigilance system . In addi-
tion, this chapter also presents in detail the reform of Directive 2010/84/EU and 
how it aims to facilitate ADR reporting in general and biologicals in particular .
•	 Chapter 4: Timely and Correct Transposition of Pharmacovigilance across 
Member States . This chapter offers a first assessment of the timeliness of national 
transposition processes for all EU Member States and shows that many countries 
have a serious transposition problem in their national pharmacovigilance systems . 
Unfortunately, it appears that the EU transposition deficit is more than just a 
statistical illusion . Almost 85 percent of the national transposition instruments 
are not transposed on time, and in fact are delayed up to more than two years . 
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Cross-country variance is significant, and the difference between the laggards 
(Denmark and Slovenia) and the champions (Cyprus, Romania, Sweden, Estonia, 
the United Kingdom and Ireland) is remarkable .
•	 Chapter 5: Practical Implementation of Pharmacovigilance in Six Member States . 
The aim of this chapter is threefold . First, it offers in-depth explanations of the 
ADR reporting systems, and describes relevant tasks and actors involved in the 
United Kingdom, Finland, France, Poland, Portugal and Germany . Second, it 
presents remaining challenges and best practices for each case as perceived 
by the interview partners . Third, it provides first recommendations on how 
to improve the existing systems in order to improve ADR reporting and help 
ensure public health .
•	 Chapter 6: Challenges and Best Practices in Perspective . This chapter offers 
an analysis of the findings presented in Chapter 5 . Here, the six different ADR 
reporting systems are directly compared and the remaining challenges and best 
practices put into perspective .
•	 Chapter 7: Conclusions and Recommendations . This chapter summarises the 
main findings that have emerged from the EU pharmacovigilance implementa-
tion assessment . On the basis of the results, the chapter outlines specific recom-
mendations in relation to the provisions of Article 2 of Directive 2010/84/EU . 
Drawing on these specific recommendations, the chapter puts forward general 
recommendations in the context of national healthcare systems, suggesting the 
constrained nature of policy options in Western democratic societies . This policy 
context is crucial for understanding questions about pharmacovigilance and its 
challenges for practical implementation across Member States .
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